

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (withdrawn and currently amended) A method of treating a human tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to [[a]] the monoclonal antibody or antigen binding fragment thereof ~~which has the identifying characteristics of a monoclonal antibody encoded~~ produced by a clone deposited with the ATCC as accession number PTA-4621, comprising administering to said mammal said monoclonal antibody in an amount effective to reduce said mammal's tumor burden.

Claim 2. (withdrawn) The method of claim 1 wherein said antibody is conjugated to a cytotoxic moiety.

Claim 3. (withdrawn) The method of claim 2 wherein said cytotoxic moiety is a radioactive isotope.

Claim 4. (withdrawn) The method of claim 1 wherein said antibody activates complement.

Claim 5. (withdrawn) The method of claim 1 wherein said antibody mediates antibody dependent cellular cytotoxicity.

Claim 6. (withdrawn) The method of claim 1 wherein said antibody is a murine antibody.

Claim 7. (withdrawn) The method of claim 1 wherein said antibody is a humanized antibody.

Claim 8. (withdrawn) The method of claim 1 wherein said antibody is a chimerized antibody.

Claim 9. (Currently Amended) [[An]] The isolated monoclonal antibody or antigen binding fragments thereof [[encoded]] produced by the clone deposited with the ATCC as PTA-4621.

Claim 10. (original) The isolated antibody or antigen binding fragments of claim 9, wherein said isolated antibody or antigen binding fragments thereof is humanized.

Claim 11. (original) The isolated antibody or antigen binding fragments of claim 9 conjugated with a member selected from the group consisting of cytotoxic moieties, enzymes, radioactive compounds, and hematogenous cells.

Claim 12. (Currently Amended) The isolated antibody or antigen binding fragments of claim 9, wherein said isolated antibody or antigen binding fragments thereof is [[a]] chimerized [[antibody]].

Claim 13. (Currently Amended) The isolated antibody or antigen binding fragments of claim 9, wherein said isolated antibody or antigen binding fragments thereof is [[a]] murine [[antibody]].

Claim 14. (original) The isolated clone deposited with the ATCC as PTA-4621.

Claim 15. (withdrawn and currently amended) A binding assay to determine a presence of cancerous cells in a tissue sample selected from a human tumor comprising:

providing a tissue sample from said human tumor;

providing [[an]] the isolated monoclonal antibody or antigen binding fragment thereof [[encoded]] produced by the clone deposited with the ATCC as PTA-4621;

contacting said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample; and

determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;

whereby the presence of said cancerous cells in said tissue sample is indicated.

Claim 16. (withdrawn) The binding assay of claim 15 wherein the human tumor tissue sample is obtained from a tumor originating in a tissue selected from the group consisting of colon, ovarian, lung, and breast tissue.

Claim 17. (withdrawn and currently amended) A process of isolating or screening for cancerous cells in a tissue sample selected from a human tumor comprising:

providing a tissue sample from [[a]] said human tumor;

providing [[an]] the isolated monoclonal antibody or antigen binding fragment thereof [[encoded]] produced by the clone deposited with the ATCC as PTA-4621;

contacting said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample; and

determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said tissue sample;

whereby

said cancerous cells are isolated by said binding and their presence in said tissue sample is confirmed.

Claim 18. (withdrawn) The process of claim 17 wherein the human tumor tissue sample is obtained from a tumor originating in a tissue selected from the group consisting of colon, ovarian, lung, and breast tissue.